Neurotrauma Assessment Test - Kansas City Concussion Testing
The Neurotrauma Assessment Test (NAT) is a highly sensitive evaluation method designed to detect the presence of specific proteins released when the brain or spinal cord suffers injury. These proteins, commonly known as biomarkers, include substances like GFAP. Following brain injury, these biomarkers are discharged into the bloodstream and are utilized as indicators of injury severity. Although biomarkers like GFAP are typically elevated immediately after injury, they can persist in the bloodstream for months afterward.
While TBI biomarkers offer valuable insights into the extent of brain injury, they represent just one facet of assessing TBI severity. Additional diagnostic tools such as CT scans or MRIs may also be necessary to comprehensively evaluate the magnitude of the brain injury.
The NAT blood test furnishes data regarding the nature and severity of brain injury, aiding in outcome prediction and treatment planning. Research into TBI biomarkers remains active, with ongoing identification and evaluation of new biomarkers. As our comprehension of TBI and the role of biomarkers in diagnosis and management advances, blood tests will play an increasingly pivotal role in TBI assessment.